Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy

Hadidi, Samer Al; Szabó, Anikó; Esselmann, Jean; Hammons, Lindsay; Hussain, Munawwar; Ogunsesan, Yetunde; Thalambedu, Nishanth; Khan, Fatima; Sethi, Jaskirat; Janardan, Abhishek; Radhakrishnan, Sabarinath Venniyil; Thanendrarajan, Sharmilan; Schinke, Carolina; Dhakal, Binod; Janz, Siegfried; Chhabra, Saurabh; D’Souza, Anita; Zangari, Maurizio; Rhee, F. Van; Mohan, Meera

doi:10.1038/s41409-022-01905-1

Cited by 11 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Because of the paucity of apheresis slots for BCMA-targeted CAR T-cell therapy in MM (SoC ide-cel and cilta-cel), select centers with access to these agents have had long wait lists. 3,4 In a study examining the clinical outcomes of patients with heavily pretreated myeloma who were enrolled in CAR T wait list, approximately one in four patients died at 1 year while waiting for CAR T and the cumulative incidence of receiving CAR T at 1 year was around 40%. 3 Another multicenter study showed that patients wait on an average of 6 months before apheresis and a quarter of patients unfortunately died while waiting for CAR T. 4 Hence, the long wait lists for CAR T in myeloma introduce a selection bias even before apheresis.…”

Section: To the Editormentioning

confidence: 99%

“…3,4 In a study examining the clinical outcomes of patients with heavily pretreated myeloma who were enrolled in CAR T wait list, approximately one in four patients died at 1 year while waiting for CAR T and the cumulative incidence of receiving CAR T at 1 year was around 40%. 3 Another multicenter study showed that patients wait on an average of 6 months before apheresis and a quarter of patients unfortunately died while waiting for CAR T. 4 Hence, the long wait lists for CAR T in myeloma introduce a selection bias even before apheresis. Excluding patients who dropout postapheresis can introduce another layer of selection bias and further complicate interpretation of efficacy.…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States

Chakraborty

Hadidi

2023

JCO

Self Cite

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 99%

Section: To the Editormentioning

confidence: 99%

Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States

Chakraborty

Hadidi

2023

JCO

Self Cite

View full text Add to dashboard Cite

“…For most of the past 2 years, patients in the United States who met FDA indications for CAR‐T have seldom been able to receive the therapy easily. A small review of the outcomes of patients referred for CAR‐T to several centers showed a dismal 40% of those patients actually obtaining the intervention, with a quarter of patients dying of MM while waiting to undergo treatment 44 . Over the past few months, the number of manufacturing slots for both commerical products appears to be increasing and this issue may become less relevant in the next year in the United States.…”

Section: Current Limitations Of Car‐tmentioning

confidence: 99%

Update on the current and future use of CAR‐T to treat multiple myeloma

Gahvari,

Brunner,

Schmidt

et al. 2023

European J of Haematology

View full text Add to dashboard Cite

Chimeric antigen receptor T‐cell (CAR‐T) therapy has become an important intervention in the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B‐cell maturation antigen (BCMA) is the most targeted surface protein due to its ubiquitous expression on plasma cells, with increasing expression of this essential transmembrane protein on malignant plasma cells as patients develop more advanced disease. This review will explore the earliest CAR‐T trials in myeloma, discuss important issues involved in CAR‐T manufacturing and processing, as well as review current clinical trials that led to the approval of the two commercially available CAR‐T products, Idecabtagene vicleucel and ciltacabtagene autoleucel. The most recent data from trials investigating the use of CAR‐T as an earlier line of therapy will be presented. Finally, the problem of relapses after CAR‐T will be presented, including several theories as to why CAR‐T therapies fail and possible clinical caveats. The next generation of MM‐specific CAR‐T will likely include new targets such as G‐protein‐coupled receptor class C, Group 5, member D (GPRC5D) and signaling lymphocyte activation molecular Family 7 (SLAMF7). The role of CAR‐T in the treatment of MM will undoubtedly increase exponentially in the next decade.

show abstract

Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable

Ailawadhi,

Shune,

Wong

et al. 2024

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy

Cited by 11 publications

References 10 publications

Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States

Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States

Update on the current and future use of CAR‐T to treat multiple myeloma

Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable

Contact Info

Product

Resources

About